{"id":2600,"date":"2026-04-21T10:00:00","date_gmt":"2026-04-21T14:00:00","guid":{"rendered":"https:\/\/glycovax.com\/?p=2600"},"modified":"2026-04-22T08:31:12","modified_gmt":"2026-04-22T12:31:12","slug":"glycovax-universite-laval-licence-galectine-3","status":"publish","type":"post","link":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/","title":{"rendered":"L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3"},"content":{"rendered":"\n
\n
\n\"Glycovax\n<\/div>\n\n\n\n
\n\"Universit\u00e9\n<\/div>\n<\/div>\n\n\n\n

L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3<\/strong><\/p>\n\n\n\n

Montr\u00e9al et Qu\u00e9bec, le 22 avril 2026<\/strong> \u2014 L\u2019Universit\u00e9 Laval et Glycovax Pharma annoncent une entente de licence mondiale exclusive accordant \u00e0 Glycovax les droits de d\u00e9veloppement et de commercialisation sur une famille de compos\u00e9s ciblant la galectine-3, une prot\u00e9ine cellulaire impliqu\u00e9e dans plusieurs processus biologiques et reconnue pour son r\u00f4le dans le d\u00e9veloppement de nombreuses maladies fibrotiques et autres pathologies.<\/p>\n\n\n\n

Cette entente repose sur une propri\u00e9t\u00e9 intellectuelle prot\u00e9g\u00e9e par des demandes de brevets d\u00e9pos\u00e9es \u00e0 l\u2019international et elle contribue \u00e0 renforcer le portefeuille de d\u00e9veloppement de Glycovax qui est bas\u00e9 sur une approche th\u00e9rapeutique \u00e0 fort potentiel.<\/p>\n\n\n\n

Une cible biologique majeure, encore sans traitement approuv\u00e9<\/strong><\/p>\n\n\n\n

La galectine-3 est \u00e9tudi\u00e9e mondialement en raison de son implication dans l\u2019inflammation, la fibrose et la progression de plusieurs pathologies chroniques. Malgr\u00e9 l\u2019int\u00e9r\u00eat soutenu pour cette cible, aucun inhibiteur de galectines n\u2019a encore \u00e9t\u00e9 approuv\u00e9 \u00e0 ce jour pour le traitement de ces maladies.<\/p>\n\n\n\n

Une innovation con\u00e7ue pour d\u00e9passer les limites observ\u00e9es<\/strong><\/p>\n\n\n\n

L\u2019\u00e9quipe du professeur Denis Gigu\u00e8re, du D\u00e9partement de chimie de l\u2019Universit\u00e9 Laval, a d\u00e9velopp\u00e9 une nouvelle g\u00e9n\u00e9ration de d\u00e9riv\u00e9s de compos\u00e9s connus visant \u00e0 combler certaines limites pharmacologiques et \u00e0 am\u00e9liorer la s\u00e9lectivit\u00e9 de la galectine-3, dans le but d\u2019optimiser le potentiel th\u00e9rapeutique de cette approche.<\/p>\n\n\n\n

Le professeur Gigu\u00e8re est un chercheur sp\u00e9cialis\u00e9 en chimie m\u00e9dicinale et synth\u00e8se de produits naturels, reconnu pour son expertise en chimie des glucides et en conception de mol\u00e9cules complexes.<\/p>\n\n\n\n

Une technologie de rupture soutenue par une solide propri\u00e9t\u00e9 intellectuelle internationale<\/strong><\/p>\n\n\n\n

Cette entente permettra de propulser une technologie de rupture, issue des travaux du professeur Gigu\u00e8re, et soutenue par une robuste propri\u00e9t\u00e9 intellectuelle internationale. En s\u2019appuyant sur une expertise exclusive en chimie des glucides et sur le savoir-faire unique de Glycovax, le programme de d\u00e9veloppement entre maintenant dans une phase d\u2019acc\u00e9l\u00e9ration visant \u00e0 faire \u00e9merger un candidat dot\u00e9 d\u2019un potentiel clinique et commercial significatif.<\/p>\n\n\n\n

Des indications \u00e0 fort impact : fibrose, maladies du foie et oncologie<\/strong><\/p>\n\n\n\n

En plus des maladies fibrotiques, dont la fibrose pulmonaire idiopathique (FPI) et la fibrose r\u00e9nale, ces nouvelles mol\u00e9cules pourraient \u00e9galement viser des maladies du foie telles que la NAFLD, la NAFL, la NASH et la cirrhose, ainsi que plusieurs types de cancers, selon les r\u00e9sultats des \u00e9tudes.<\/p>\n\n\n\n

La FPI affecte environ 15\u2009000 personnes au Canada, 100\u2009000 aux \u00c9tats-Unis et 200\u2009000 en Europe. La valeur du march\u00e9 global du traitement de la FPI \u00e9tait estim\u00e9e \u00e0 2,47 milliards USD en 2019 et pourrait atteindre 3,59 milliards USD en 2029. Quant \u00e0 la NASH, elle affecte environ 38 millions d\u2019Am\u00e9ricains, 10 millions d\u2019Europ\u00e9ens et 1,5 million de Canadiens.<\/p>\n\n\n\n

Professeur Denis Gigu\u00e8re, D\u00e9partement de chimie, Universit\u00e9 Laval<\/strong><\/p>\n\n\n\n

 \u00ab\u2009Notre \u00e9quipe a travaill\u00e9 intensivement afin de surmonter des d\u00e9fis scientifiques importants et de d\u00e9velopper de nouvelles solutions ciblant la galectine-3. Ce partenariat avec Glycovax Pharma permet d\u2019acc\u00e9l\u00e9rer la valorisation de nos travaux et de les faire progresser vers des applications th\u00e9rapeutiques concr\u00e8tes. \u00bb<\/p>\n\n\n\n

Dany Valiquette, chef de la direction, Glycovax Pharma<\/strong><\/p>\n\n\n\n

 \u00ab\u2009Cette entente s\u2019inscrit dans notre mission qui est de propulser des innovations de rupture, issues des travaux de chercheurs de calibre mondial, vers des solutions th\u00e9rapeutiques efficaces et accessibles, qui nous permettent de b\u00e2tir un actif strat\u00e9gique \u00e0 fort potentiel clinique et commercial. \u00bb<\/p>\n\n\n\n

\u00c0 propos de Glycovax Pharma inc.<\/strong><\/p>\n\n\n\n

Fond\u00e9e en 2016, Glycovax Pharma est une soci\u00e9t\u00e9 biopharmaceutique canadienne sp\u00e9cialis\u00e9e dans la conception et le d\u00e9veloppement de technologies cl\u00e9s pour la prochaine g\u00e9n\u00e9ration de vaccins conjugu\u00e9s humains et v\u00e9t\u00e9rinaires. Gr\u00e2ce \u00e0 son expertise unique en glyco-immunologie, Glycovax se positionne \u00e0 l\u2019avant-garde de solutions vaccinales plus efficaces, particuli\u00e8rement dans les domaines des infections virales ou bact\u00e9riennes et du cancer.<\/p>\n\n\n\n

Pour plus d\u2019information, visitez : www.glycovax.com<\/a><\/p>\n\n\n\n

Pour information<\/strong><\/p>\n\n\n\n

Universit\u00e9 Laval<\/strong>
ULaval communications
medias@ulaval.ca<\/a>
T. 418\u00a0656-3355<\/p>\n\n\n\n

Glycovax Pharma<\/strong>
Daniel Granger
Daniel.granger@acjcommunication.com<\/a>
T. 514\u00a0232 1556<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3 Montr\u00e9al et Qu\u00e9bec, le 22 avril 2026 \u2014 L\u2019Universit\u00e9 Laval et Glycovax Pharma annoncent une entente de licence mondiale exclusive accordant \u00e0 Glycovax les droits de d\u00e9veloppement et de commercialisation sur une famille de compos\u00e9s ciblant…<\/p>\n","protected":false},"author":2,"featured_media":2606,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[96],"tags":[],"class_list":["post-2600","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse"],"acf":[],"yoast_head":"\nGlycovax et l'Universit\u00e9 Laval : licence mondiale sur la galectine-3<\/title>\n<meta name=\"description\" content=\"Glycovax Pharma et l'Universit\u00e9 Laval concluent une entente de licence mondiale exclusive sur des inhibiteurs brevet\u00e9s ciblant la galectine-3, pour traiter la FPI, la NASH et le cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glycovax et l'Universit\u00e9 Laval : licence mondiale sur la galectine-3\" \/>\n<meta property=\"og:description\" content=\"Glycovax Pharma et l'Universit\u00e9 Laval concluent une entente de licence mondiale exclusive sur des inhibiteurs brevet\u00e9s ciblant la galectine-3, pour traiter la FPI, la NASH et le cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Glycovax Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T14:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-22T12:31:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Claude Dagenais\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Claude Dagenais\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/\"},\"author\":{\"name\":\"Claude Dagenais\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\"},\"headline\":\"L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3\",\"datePublished\":\"2026-04-21T14:00:00+00:00\",\"dateModified\":\"2026-04-22T12:31:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/\"},\"wordCount\":736,\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/\",\"name\":\"Glycovax et l'Universit\u00e9 Laval : licence mondiale sur la galectine-3\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"datePublished\":\"2026-04-21T14:00:00+00:00\",\"dateModified\":\"2026-04-22T12:31:12+00:00\",\"description\":\"Glycovax Pharma et l'Universit\u00e9 Laval concluent une entente de licence mondiale exclusive sur des inhibiteurs brevet\u00e9s ciblant la galectine-3, pour traiter la FPI, la NASH et le cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"name\":\"Glycovax Pharma\",\"description\":\"Saving millions of lives by using the power of advanced medical nanotechnology.\",\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"alternateName\":\"Glycovax\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\",\"name\":\"Glycovax Pharma\",\"alternateName\":\"Glycovax\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"width\":1200,\"height\":1200,\"caption\":\"Glycovax Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\",\"name\":\"Claude Dagenais\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"caption\":\"Claude Dagenais\"},\"sameAs\":[\"https:\\\/\\\/twohumans.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glycovax et l'Universit\u00e9 Laval : licence mondiale sur la galectine-3","description":"Glycovax Pharma et l'Universit\u00e9 Laval concluent une entente de licence mondiale exclusive sur des inhibiteurs brevet\u00e9s ciblant la galectine-3, pour traiter la FPI, la NASH et le cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/","og_locale":"fr_FR","og_type":"article","og_title":"Glycovax et l'Universit\u00e9 Laval : licence mondiale sur la galectine-3","og_description":"Glycovax Pharma et l'Universit\u00e9 Laval concluent une entente de licence mondiale exclusive sur des inhibiteurs brevet\u00e9s ciblant la galectine-3, pour traiter la FPI, la NASH et le cancer.","og_url":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/","og_site_name":"Glycovax Pharma","article_published_time":"2026-04-21T14:00:00+00:00","article_modified_time":"2026-04-22T12:31:12+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","type":"image\/jpeg"}],"author":"Claude Dagenais","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Claude Dagenais","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#article","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/"},"author":{"name":"Claude Dagenais","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883"},"headline":"L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3","datePublished":"2026-04-21T14:00:00+00:00","dateModified":"2026-04-22T12:31:12+00:00","mainEntityOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/"},"wordCount":736,"publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"image":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#primaryimage"},"thumbnailUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/","url":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/","name":"Glycovax et l'Universit\u00e9 Laval : licence mondiale sur la galectine-3","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#primaryimage"},"image":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#primaryimage"},"thumbnailUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","datePublished":"2026-04-21T14:00:00+00:00","dateModified":"2026-04-22T12:31:12+00:00","description":"Glycovax Pharma et l'Universit\u00e9 Laval concluent une entente de licence mondiale exclusive sur des inhibiteurs brevet\u00e9s ciblant la galectine-3, pour traiter la FPI, la NASH et le cancer.","breadcrumb":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#primaryimage","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycovax.com\/fr\/"},{"@type":"ListItem","position":2,"name":"L\u2019Universit\u00e9 Laval et Glycovax Pharma concluent une entente de licence mondiale exclusive pour le d\u00e9veloppement d\u2019inhibiteurs innovants de galectine-3"}]},{"@type":"WebSite","@id":"https:\/\/glycovax.com\/fr\/#website","url":"https:\/\/glycovax.com\/fr\/","name":"Glycovax Pharma","description":"Saving millions of lives by using the power of advanced medical nanotechnology.","publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"alternateName":"Glycovax","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycovax.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/glycovax.com\/fr\/#organization","name":"Glycovax Pharma","alternateName":"Glycovax","url":"https:\/\/glycovax.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","width":1200,"height":1200,"caption":"Glycovax Pharma"},"image":{"@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883","name":"Claude Dagenais","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","caption":"Claude Dagenais"},"sameAs":["https:\/\/twohumans.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/comments?post=2600"}],"version-history":[{"count":5,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2600\/revisions"}],"predecessor-version":[{"id":2637,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2600\/revisions\/2637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media\/2606"}],"wp:attachment":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media?parent=2600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/categories?post=2600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/tags?post=2600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}